干扰素α诱导蛋白27在肿瘤中致癌作用的泛癌分析

doi:10.13591/j.cnki.kqyx.2026.08.006

摘要/Abstract

摘要：

目的探讨IFI27基因在不同癌症中的表达差异及其作为疾病预后潜在标志物的可行性。方法基于癌症基因组图谱(TCGA)数据库,利用多种在线分析工具及R语言软件对33种癌症类型中的IFI27基因表达水平进行泛癌分析,包括头颈鳞状细胞癌、前列腺癌等。评估IFI27基因的突变形式和DNA甲基化与mRNA表达的关系,分析IFI27表达与肿瘤免疫浸润的相关性,同时对IFI27的相互作用基因进行KEGG和GO富集分析。结果基于TIMER 2.0及GEPIA2的综合分析,IFI27在12种肿瘤组织中显著上调,而在3种癌症中则表现为下调。IFI27基因的突变主要表现为拷贝数变异,其mRNA表达水平与启动子甲基化水平呈负相关。此外,IFI27表达水平与头颈鳞状细胞癌和葡萄膜黑色素瘤中的CD8⁺ T细胞浸润程度有显著正相关性,在前列腺癌和甲状腺癌中,肿瘤相关成纤维细胞的浸润程度受到IFI27表达水平的影响,且两者之间存在正相关关系。结论 IFI27的表达水平在多种癌症中较正常组织显著上调,并影响患者的生存预后。IFI27可作为头颈鳞状细胞癌、胸腺瘤、葡萄膜黑色素瘤、皮肤黑色素瘤、低级别胶质瘤和卵巢浆液性腺癌的预后标志物。

关键词: 干扰素α诱导蛋白27, 致癌基因, 存活率, 拷贝数变异, 免疫细胞浸润

Abstract:

Objective To investigate the differential expression of the IFI27 gene across various cancers and evaluate its potential as a prognostic biomarker. Methods A pan-cancer analysis was conducted using data from The Cancer Genome Atlas(TCGA) database, incorporating multiple online tools and R software to analyze IFI27 expression in 33 types of cancer, including head and neck squamous cell carcinoma, prostate cancer, and others. The study assessed the relationship between IFI27 gene mutations, DNA methylation, and mRNA expression levels, as well as the correlation between IFI27 expression and tumor immune infiltration. Additionally, the interacting genes of IFI27 were subjected to KEGG and GO enrichment analysis. Results Based on integrated analysis using TIMER2.0 and GEPIA2, IFI27 expression was significantly upregulated in 12 types of cancer tissues, while it was downregulated in 3 types. IFI27 mutations were primarily characterized by copy number variations, and its mRNA expression level was negatively correlated with promoter methylation. Moreover, IFI27 expression was significantly positively correlated with CD8⁺ T cell infiltration in head and neck squamous cell carcinoma and uveal melanoma. In prostate cancer and thyroid cancer, the infiltration level of tumor-associated fibroblasts was influenced by IFI27 expression, with a positive correlation observed between them. Conclusion The expression of IFI27 is significantly upregulated in various cancers compared to normal tissues and has an impact on patient survival outcomes. IFI27 may serve as a prognostic biomarker for head and neck squamous cell carcinoma, thymoma, uveal melanoma, skin cutaneous melanoma, low-grade glioma, and ovarian serous adenocarcinoma.

Key words: interferon alpha-inducible protein 27(IFI27), oncogene, survival rate, copy number variation, immune cell infiltration

中图分类号:

R730

陈汉, 李璐璐, 李宏卫. 干扰素α诱导蛋白27在肿瘤中致癌作用的泛癌分析[J]. 口腔医学, 2026, 46(8): 598-608.

CHEN Han, LI Lulu, LI Hongwei. Pan-cancer analysis of the oncogenic role of interferon alpha-inducible protein 27 in tumors[J]. Stomatology, 2026, 46(8): 598-608.

图/表 7

图1

图2

图3

图4

图5

图6

图7

参考文献 31

[1]	Clough E, Barrett T. The gene expression omnibus database[J]. Methods Mol Biol, 2016, 1418: 93-110. doi: 10.1007/978-1-4939-3578-9_5 pmid: 27008011
[2]	Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): An immeasurable source of knowledge[J]. Contemp Oncol, 2015, 19(1A): A68-A77.
[3]	Shojaei M, McLean AS. Interferon-stimulated gene IFI27 as a multifaceted candidate target in precision medicine[J]. Trends Immunol, 2025, 46(3): 219-228. doi: 10.1016/j.it.2025.01.008 pmid: 40044530
[4]	Butt DQ, Harun MH, Che Jalil NA, et al. Protumorigenic interferon-stimulated genes in cancer: A comprehensive review[J]. Cureus, 2024, 16(6): e63216.
[5]	Gytz H, Hansen MF, Skovbjerg S, et al. Apoptotic properties of the type 1 interferon induced family of human mitochondrial membrane ISG12 proteins[J]. Biol Cell, 2017, 109(2): 94-112. doi: 10.1111/boc.201600034 pmid: 27673746
[6]	Rosebeck S, Leaman DW. Mitochondrial localization and pro-apoptotic effects of the interferon-inducible protein ISG12a[J]. Apoptosis, 2008, 13(4): 562-572. doi: 10.1007/s10495-008-0190-0 pmid: 18330707
[7]	Malhotra S, Bustamante MF, Pérez-Miralles F, et al. Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis[J]. PLoS One, 2011, 6(8): e23634. doi: 10.1371/journal.pone.0023634
[8]	Papac-Milicevic N, Breuss JM, Zaujec J, et al. The interferon stimulated gene 12 inactivates vasculoprotective functions of NR4A nuclear receptors[J]. Circ Res, 2012, 110(8): e50-e63.
[9]	Gjermandsen IM, Justesen J, Martensen PM. The interferon-induced gene ISG12 is regulated by various cytokines as the gene 6-16 in human cell lines[J]. Cytokine, 2000, 12(3): 233-238. pmid: 10704250
[10]	Li TW, Fu JX, Zeng ZX, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells[J]. Nucleic Acids Res, 2020, 48(W1): W509-W514. doi: 10.1093/nar/gkaa407
[11]	Tang ZF, Kang BX, Li CW, et al. GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis[J]. Nucleic Acids Res, 2019, 47(W1): W556-W560. doi: 10.1093/nar/gkz430
[12]	Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN aportal for facilitating tumor subgroup gene expression and survival analyses[J]. Neoplasia, 2017, 19(8): 649-658. doi: S1476-5586(17)30179-3 pmid: 28732212
[13]	Cerami E, Gao JJ, Dogrusoz U, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data[J]. Cancer Discov, 2012, 2(5): 401-404. doi: 10.1158/2159-8290.CD-12-0095 pmid: 22588877
[14]	Rui R, Zhou LQ, He SM. Cancer immunotherapies: Advances and bottlenecks[J]. Front Immunol, 2023, 14: 1212476. doi: 10.3389/fimmu.2023.1212476
[15]	de Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth[J]. Cancer Cell, 2023, 41(3): 374-403. doi: 10.1016/j.ccell.2023.02.016 pmid: 36917948
[16]	Kennel KB, Bozlar M, De ValkAF, et al. Cancer-associated fibroblasts in inflammation and antitumor immunity[J]. Clin Cancer Res, 2023, 29(6): 1009-1016. doi: 10.1158/1078-0432.CCR-22-1031
[17]	Arpinati L, Scherz-Shouval R. From gatekeepers to providers: Regulation of immune functions by cancer-associated fibroblasts[J]. Trends Cancer, 2023, 9(5): 421-443. doi: 10.1016/j.trecan.2023.01.007 pmid: 36870916
[18]	Bardou P, Mariette J, Escudié F, et al. Jvenn: An interactive Venn diagram viewer[J]. BMC Bioinformatics, 2014, 15(1): 293. doi: 10.1186/1471-2105-15-293
[19]	Tang DD, Chen MJ, Huang XH, et al. SRplot: A free online platform for data visualization and graphing[J]. PLoS One, 2023, 18(11): e0294236. doi: 10.1371/journal.pone.0294236
[20]	Padzińska-PruszyńskaI B, Taciak B, Kiraga Ł, et al. Targeting cancer: Microenvironment and immunotherapy innovations[J]. Int J Mol Sci, 2024, 25(24): 13569. doi: 10.3390/ijms252413569
[21]	Chen YX, Yu DN, Qian H, et al. CD8⁺T cell-based cancer immunotherapy[J]. J Transl Med, 2024, 22(1): 394. doi: 10.1186/s12967-024-05134-6
[22]	Zhou DE, Zheng L. Recent advances in cancer-associated fibroblast: Biomarkers, signaling pathways, and therapeutic opportunities[J]. Chin Med J, 2024, 137(6): 638-650. doi: 10.1097/CM9.0000000000003031
[23]	Xu L, Zu TJ, Li T, et al. ATF3 downmodulates its new targets IFI6 and IFI27 to suppress the growth and migration of tongue squamous cell carcinoma cells[J]. PLoS Genet, 2021, 17(2): e1009283. doi: 10.1371/journal.pgen.1009283
[24]	Chiang KC, Huang ST, Wu RC, et al. Interferon α-inducible protein 27 is an oncogene and highly expressed in cholangiocarcinoma patients with poor survival[J]. Cancer Manag Res, 2019, 11: 1893-1905. doi: 10.2147/CMAR
[25]	Villamayor L, López-García D, Rivero V, et al. The IFN-stimulated gene IFI27 counteracts innate immune responses after viral infections by interfering with RIG-I signaling[J]. Front Microbiol, 2023, 14: 1176177. doi: 10.3389/fmicb.2023.1176177
[26]	Girone C, Calati F, Lo Cigno I, et al. The RIG-I agonist M8 triggers cell death and natural killer cell activation in human papillomavirus-associated cancer and potentiates cisplatin cytotoxicity[J]. Cancer Immunol Immunother, 2023, 72(9): 3097-3110. doi: 10.1007/s00262-023-03483-7 pmid: 37356050
[27]	Li SQ, Xie Y, Zhang W, et al. Interferon alpha-inducible protein 27 promotes epithelial-mesenchymal transition and induces ovarian tumorigenicity and stemness[J]. J Surg Res, 2015, 193(1): 255-264. doi: 10.1016/j.jss.2014.06.055 pmid: 25103640
[28]	Mandahl N, Mertens F, Mitelman F. Gene amplification in neoplasia: A cytogenetic survey of 80 131 cases[J]. Genes Chromosomes Cancer, 2024, 63(1): e23214. doi: 10.1002/gcc.v63.1
[29]	Nozawa H, Oda E, Ueda S, et al. Functionally inactivating point mutation in the tumor-suppressor IRF-1 gene identified in human gastric cancer[J]. Int J Cancer, 1998, 77(4): 522-527. doi: 10.1002/(sici)1097-0215(19980812)77:4<522::aid-ijc8>3.0.co;2-w pmid: 9679752
[30]	Purbey PK, Seo J, Paul MK, et al. Opposing tumor-cell-intrinsic and-extrinsic roles of the IRF1 transcription factor in antitumor immunity[J]. Cell Rep, 2024, 43(6): 114289. doi: 10.1016/j.celrep.2024.114289
[31]	Bhandarkar V, Dinter T, Spranger S. Architects of immunity: How dendritic cells shape CD8⁺ T cell fate in cancer[J]. Sci Immunol, 2025, 10(103): eadf4726.